Shares of Oxigene Inc (NASDAQ:OXGN) more than doubled on very heavy volume after the microcap biotech said a mid-stage study of its drug Zybrestat, when used with Roche’s Avastin, showed increased survival in ovarian cancer patients. OXiGENE Inc (NASDAQ:OXGN) stock performance was 17.48% in last session and finished the day at $2.42. Traded volume was 6,334,713 million shares in the last session and the average volume of the stock remained438.53 million shares. The beta of the stock remained 2.72. OXiGENE Inc (NASDAQ:OXGN) insider ownership is 0.10%.

AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) on Feb. 4 announced that an article on Phase 2 results for zoptarelin doxorubicin (AEZS-108) in endometrial cancer has been published in the February issue of the International Journal of Gynecological Cancer. AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) rose 16.41 percent to $1.49 yesterday on volume of 5.14 million shares. The intra-day range of the stock was $1.26 to $1.52. AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) has a market capitalization of $83.90million.

US RNAi-based drug discover Marina Biotech (Nasdaq:MRNA) says that it plans to broadly apply its RNAi, antisense and microRNA therapeutics platform to develop drugs for rare diseases. Marina Biotech, Inc. (OTCMKTS:MRNA)’s stock on Mar 11, 2014 reported a increase of 16.67% to the closing price of $1.40. Its fifty two weeks range is $0.18 -$1.81. The total market capitalization recorded $22.91 million. The overall volume in the last trading session was 585,855 million shares. In its share capital, Marina Biotech, Inc. (OTCMKTS:MRNA) has 9.14million outstanding shares.

Zacks initiated coverage on shares of Dicerna Pharmaceuticals (NASDAQ:DRNA) in a research report issued to clients and investors on Wednesday, ARN reports. The firm set a “hold” rating on the stock. On Tuesday, shares of Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) advanced 5.21% to close the day at $38.37. Company return on investment (ROI) is 16.60% and its monthly performance is recorded as 8.57%.